Skip to content

Sex-dependent Effects of Flavanols on Vascular Status

Sex-dependent Effects of Flavanol Metabolism and Absorption on Vascular Status

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02147223
Enrollment
24
Registered
2014-05-26
Start date
2013-11-30
Completion date
2014-11-30
Last updated
2015-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases

Keywords

flavanols, sex-related cardiovascular effects

Brief summary

Epidemiological studies suggest that certain foods rich in flavanols, including cocoa products, red wine, and tea, are associated with decreased cardiovascular mortality and morbidity. Dietary interventional studies have corroborated this finding and showed that flavanols can acutely and after sustained ingestion improve surrogate markers of cardiovascular risk including endothelial function. Endothelial dysfunction is the key event in the development and progression of cardiovascular disease. The aim of the study is to assess sex specific effects of cocoa flavanols on endothelial and vascular function in healthy subjects.

Interventions

DIETARY_SUPPLEMENTFlavanol rich intervention

Flavanol intervention products (250 mg, 500 mg and 750 mg flavanols)

DIETARY_SUPPLEMENTFlavanol free intervention

Calorically, micro- and macronutrient matched control product free of flavanols

Sponsors

Heinrich-Heine University, Duesseldorf
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* healthy post-menopausal femal subjects (\>50 years) * healthy male subjects (\>50 years)

Exclusion criteria

* acute inflammation * cardiac arrhythmia * renal failure * heart failure (NYHA II-IV) * diabetes mellitus * CRP \> 1 mg/dl * malignant disease

Design outcomes

Primary

MeasureTime frame
Absolute change of Flow-mediated Vasodilation (FMD)2 hours

Secondary

MeasureTime frameDescription
Ambulatory blood pressure2 hoursautomatical measurements
Plasma flavanol metabolites2 hoursMeasured by HPLC
laboratory safety parameters2 hoursblood/urine samples for safety assessment (haematology, biochemistry, and urinalysis)
Pulse wave velocity2 hoursMeasured by SphygmoCor
Augmentation index2 hoursMeasured by SphygmoCor

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026